Compounds and compositions as LXR modulators

Details Compounds and compositions as LXR modulators Compounds and compositions as LXR modulators

2005-02-11

2010-12-07

Zucker, Paul A (Department: 1621)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S378000, C514S406000, C514S359000, C546S335000, C548S242000, C548S373100, C560S041000

Reexamination Certificate

active

07846949

ABSTRACT:
The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of liver X receptors (LXRs).

REFERENCES:
patent: 5110348 (1992-05-01), Hopwood
patent: 516523 (1969-11-01), None
patent: 516523 (1971-12-01), None
patent: 1185194 (1965-01-01), None
patent: 1340750 (2003-09-01), None
patent: 1236091 (1971-06-01), None
patent: 56083458 (1981-07-01), None
patent: 07258224 (1995-10-01), None
patent: 11001456 (1999-01-01), None
Greene, Protective Groups in Organic Chemistry, 1981, John Wiley & Sons, Inc., pp. 158-169.
Evans et al., “Some substituted phenylalkanoic acids and N-substituted malonailic, succinanillic, and anilinoalkanoic acids as potential antiinflammatory agents.”, Journal of Medicinal Chemistry, vol. 12, No. 6, pp. 1006-1010, 1969.
Larizza A., “N-aryl-N-aroylamino acid derivatives.”, Journal of Medicinal Chemistry, vol. 13, No. 5, pp. 1019-1020, 1970.
Cao et al., “Antidiabetic Action of a Liver X Receptor Agonist Mediated by Inhibition of Hepatic Gluconeogenesis”, Journal of Biological Chemistry, vol. 278, pp. 1131-1136, 2003.
Cao et al., “Liver X Receptors as Potential Therapeutic Targets for Multiple Diseases”, Drug News Perspect., vol. 17, pp. 35-41, 2004.
Chin et al., “Miniaturization of Cell-Based b-Lactamase-Dependent FRET Assays to Ultra-High Throughput Formats to Identify Agonists of Human Liver X Receptors”, Assay and Drug Development Technologies, vol. 1, pp. 777-787, 2003.
Collins et al., “Identification of a Nonsteroidal Liver X Receptor Agonist through Parallel Array Synthesis of Tertiary Amines”, Journal of Medicinal Chemistry, vol. 45, pp. 1963-1966, 2002.
Fowler et al., “Liver X Receptor Activators Display Anti-Inflammatory Activity in Irritant and Allergic Contact Dermatitis Models: Liver-X-Receptor-Specific Inhibition of Inflammation and Primary Cytokine Production”, J Invest Dermatol., vol. 120, pp. 246-255, 2003.
Jaye, Micheal, “LXR agonists for the treatment of atherosclerosis”, Current Opinion in Investigational Drugs, vol. 4, pp. 1053-1058, 2003.
Joseph et al., “Synthetic LXR ligand inhibits the development of atherosclerosis in mice”, PNAS, vol. 99, pp. 7604-7609, 2002.
Josepg et al., “Reciprocal regulation of inflammation and lipid metabolism by liver X receptors”, Nature Medicine, vol. 9, pp. 213-219, 2003.
Joseph et al., “LXRs: new therapeutic targets in atherosclerosis?”, Current Opinion in Pharmacology, vol. 3, pp. 192-197, 2003.
Lafitte et al., “Activation of liver X receptor improves glucose tolerance through coordinate regulation of glucose metabolism in liver and adipose tissue”, PNAS, vol. 100, pp. 5419-5424, 2003.
Lehmann et al., “Activation of the Nuclear Receptor LXR by Oxysterols Defines a New Hormone Response Pathway”, Journal of Biological Chemistry, vol. 272, pp. 3137-3140, 1997.
Repa et al., “Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta”, Genes & Development, vol. 14, pp. 2819-2830, 2000.
Schultz et al., “Role of LXRs in control of lipogenesis”, Genes & Development, vol. 14, pp. 2831-2838, 2000.
Spencer et al., “Pharmacophore Analysis of the Nuclear Oxysterol Receptor LXRalpha”, Journal of Medicinal Chemistry, vol. 44, pp. 886-897, 2001.
Tangiralla et al., “Identification of macrophage liver X receptors as inhibitors of atherosclerosis”, PNAS, vol. 99, pp. 11896-11901, 2002.
Terasaka et al., “T-0901317, a synthetic liver X receptor ligand, inhibits development of atherosclerosis in LDL receptor-deficient mice”, FEBS Letters, vol. 536, pp. 6-11, 2003.
Tontonoz et al., “Liver X Receptor Signaling Pathways in Cardiovascular Disease”, Mol. Endocrinol., vol. 17, pp. 985-993, 2003.

Affiliated with

Also associated with

Rating

Compounds and compositions as LXR modulators does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compounds and compositions as LXR modulators, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds and compositions as LXR modulators will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4237175